Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marshall A Mazepa

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Blood|June 21, 2019
How targeted therapy disrupts the treatment paradigm for acquired TTP: the risks, benefits, and unknownsMarshall A Mazepa, Camila Masias, Shruti Chaturvedi
Journal of Clinical Medicine|September 28, 2023
Cardiovascular Disease and Stroke in Immune TTP-Challenges and OpportunitiesSenthil Sukumar, Marshall A Mazepa, Shruti Chaturvedi
Journal of Thrombosis and Haemostasis : JTH|October 25, 2025
Updated ISTH thrombotic thrombocytopenic purpura guidelines 2025-a bridge to the future for congenital thrombotic thrombocytopenic purpuraCharlotte M Story, Marshall A Mazepa, Shruti Chaturvedi
Transfusion Medicine Reviews|October 25, 2019
Taking Empiricism out of Immune Thrombotic Thrombocytopenic Purpura: Current and Future Treatment StrategiesMarshall A Mazepa, Yara A Park, Jay S Raval
American Journal of Clinical Pathology|April 10, 2014
Pathology consultation on electronic crossmatchMarshall A Mazepa, Jay S Raval, Yara A Park, et al.
Journal of Clinical Apheresis|August 1, 2016
Monitoring therapeutic apheresis utilization: Database versus registryJay S Raval, Marshall A Mazepa, Herbert C Whinna, et al.
Journal of Clinical Apheresis|November 19, 2017
Treatment of acquired Thrombotic Thrombocytopenic Purpura in the U.S. remains heterogeneous: Current and future points of clinical equipoiseMarshall A Mazepa, Jay S Raval, Mark E Brecher, et al.
Transfusion|July 30, 2014
How we approach an acquired thrombotic thrombocytopenic purpura patientJay S Raval, Marshall A Mazepa, Mark E Brecher, et al.
Journal of Clinical Apheresis|May 26, 2020
Heterogeneity of diagnosis, treatment, and management for immune thrombotic thrombocytopenic purpura: Are we still peering through the looking glass?Jay S Raval, Marian A Rollins-Raval, Marshall A Mazepa, et al.
British Journal of Haematology|December 19, 2013
Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpuraMarshall A Mazepa, Jay S Raval, Stephan Moll, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Blood|June 21, 2019
How targeted therapy disrupts the treatment paradigm for acquired TTP: the risks, benefits, and unknownsMarshall A Mazepa, Camila Masias, Shruti Chaturvedi
Journal of Clinical Medicine|September 28, 2023
Cardiovascular Disease and Stroke in Immune TTP-Challenges and OpportunitiesSenthil Sukumar, Marshall A Mazepa, Shruti Chaturvedi
Journal of Thrombosis and Haemostasis : JTH|October 25, 2025
Updated ISTH thrombotic thrombocytopenic purpura guidelines 2025-a bridge to the future for congenital thrombotic thrombocytopenic purpuraCharlotte M Story, Marshall A Mazepa, Shruti Chaturvedi
Transfusion Medicine Reviews|October 25, 2019
Taking Empiricism out of Immune Thrombotic Thrombocytopenic Purpura: Current and Future Treatment StrategiesMarshall A Mazepa, Yara A Park, Jay S Raval
American Journal of Clinical Pathology|April 10, 2014
Pathology consultation on electronic crossmatchMarshall A Mazepa, Jay S Raval, Yara A Park, et al.
Journal of Clinical Apheresis|August 1, 2016
Monitoring therapeutic apheresis utilization: Database versus registryJay S Raval, Marshall A Mazepa, Herbert C Whinna, et al.
Journal of Clinical Apheresis|November 19, 2017
Treatment of acquired Thrombotic Thrombocytopenic Purpura in the U.S. remains heterogeneous: Current and future points of clinical equipoiseMarshall A Mazepa, Jay S Raval, Mark E Brecher, et al.
Transfusion|July 30, 2014
How we approach an acquired thrombotic thrombocytopenic purpura patientJay S Raval, Marshall A Mazepa, Mark E Brecher, et al.
Journal of Clinical Apheresis|May 26, 2020
Heterogeneity of diagnosis, treatment, and management for immune thrombotic thrombocytopenic purpura: Are we still peering through the looking glass?Jay S Raval, Marian A Rollins-Raval, Marshall A Mazepa, et al.
British Journal of Haematology|December 19, 2013
Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpuraMarshall A Mazepa, Jay S Raval, Stephan Moll, et al.
Pageof 3